Selected article for: "acid ribonucleic and acute respiratory syndrome coronavirus"
Author: Spera, Anna Maria
Title: Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review
  • Cord-id: 8mih1fm6
  • Document date: 2021_3_25
    • ID: 8mih1fm6
    Snippet: Coronavirus disease 2019 (COVID-19) is global pandemic with various clinical presentations, ranging from cold to sometimes unrecoverable acute respiratory distress syndrome. Although urgently needed, currently there are no specific treatments for COVID-19. Repurposing existing pharmaceuticals to treat COVID-19 is crucial to control the pandemic. In silico and in vitro studies suggest that a nucleotide inhibitor called Sofosbuvir, has also antiviral activity against severe acute respiratory syndr
    Document: Coronavirus disease 2019 (COVID-19) is global pandemic with various clinical presentations, ranging from cold to sometimes unrecoverable acute respiratory distress syndrome. Although urgently needed, currently there are no specific treatments for COVID-19. Repurposing existing pharmaceuticals to treat COVID-19 is crucial to control the pandemic. In silico and in vitro studies suggest that a nucleotide inhibitor called Sofosbuvir, has also antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), apart from suppressing other positive-strand ribonucleic Acid viruses with conserved polymerase (hepatitis C virus). The aim of this study was to assess if Sofosbuvir improves clinical outcomes in patients with moderate or severe COVID-19. A compre-hensive overview of scientific literature has been made. Terms searched in PubMed were: COVID-19, SARS-CoV-2, nucleotide inhibitors, pandemic, Sofosbuvir. Results clinical trials conducted among adults with moderate or severe COVID-19 were analyzed. Patients were divided in treatment and control arms, receiving Sofosbuvir plus standard care and standard care alone respectively. The addition of Sofosbuvir to standard care significantly reduced the duration of hospital stay compared with standard care alone in clinical trials examined. If efficacy of these repurposed, cheap and easily available drug against SARS-CoV-2 is further demonstrated, it could be essential to refine the treatment of COVID-19.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and ace receptor target: 1
    • abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and acute shock: 1, 2, 3, 4, 5, 6, 7, 8
    • abdominal pain and liver cirrhosis: 1, 2, 3
    • abdominal pain and lopinavir ritonavir: 1, 2, 3, 4
    • ace receptor and active form: 1, 2
    • ace receptor and active site: 1, 2, 3, 4
    • ace receptor and acute lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • ace receptor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ace receptor and acute shock: 1, 2
    • ace receptor and acute shock respiratory distress syndrome: 1
    • ace receptor and liver cirrhosis: 1
    • ace receptor and local lung: 1
    • ace receptor and lopinavir ritonavir: 1, 2, 3
    • ace receptor and lopinavir twice daily mg ritonavir: 1
    • ace receptor target and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
    • acid precursor and active form: 1, 2
    • acid precursor and acute respiratory syndrome: 1
    • active form and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25